MOLECULAR SUBTYPES OF MUSCULAR INVASIVE BLADDER CANCER

Keywords: Bladder cancer, molecular classifi cation, personalized therapy

Abstract

This review analyzes the current view on molecular subtypes of muscle-invasive bladder cancer (MI-BC), its key biomarkers, and recommended treatment approaches. Several variants of molecular classifications of BC are known, including the classification of Baylor College of Medicine (BCM), the University of North Carolina (UNC), the MD Anderson Cancer Center (MDA), the Atlas Cancer Genome Project (TCGA), and Lund (Sweden). Nowadays, a consensus international classification of MI-BC has been developed, which not only deepened understanding of the biology of the BC but also showed the relationship of certain genomic disorders with specific morphological subtypes, as well as the clinical pass of the BC. The developed variants of molecular classifications of MI-BC allow not only to predict the course of the tumour process but also stratify patients according to the likely response to chemotherapy and immunotherapy. However, the implementation of molecular classification of MI-BC into clinical practice has several limitations and requires validation studies

Downloads

Download data is not yet available.

References

Adam RM, DeGraff DJ. Molecular mechanisms of squamous differentiation in urothelial cell carcinoma: A paradigm for molecular subtyping of urothelial cell carcinoma of the bladder. Urol Oncol. 2015:33 (10): 444-50. https://doi.org/10.1016/j.urolonc.2015.06.006 PMid:26254697

Aine M, Eriksson P, Liedber F, Sjödahl G, Höglund M. Biological determinants of bladder cancer gene expression subtypes. Sci Rep. 2015; 5: 10957. https://doi.org/10.1038/srep10957 PMid:26051783 PMCid:PMC4650643

Aine M, Eriksson P, Liedberg F, Höglund M, Sjödahl G. On Molecular Classification of Bladder Cancer: Out of One, Many. Eur. Urol. 2015; 68: 921-923.doi: 10.1016 / j.eururo.2015.07.021. https://doi.org/10.1016/j.eururo.2015.07.021 PMid:26215606

Bernardo C, Eriksson P, Marzouka N, Liedberg F, Sjödahl G, Höglund M. Molecular pathology of the luminal class of urothelial tumors J Pathol. 2019; 249 (3): 308-318. doi: 10.1002 / path.5318. https://doi.org/10.1002/path.5318 PMid:31232464 PMCid:PMC6851980

Biton A, Bernard-Pierrot I, Lou Y, Krucker C, Chapeaublanc E, Rubio-Pérez C. et al. Independent analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes. Cell Rep. 2014; 9 (4): 1235-1245. https://doi.org/10.1016/j.celrep.2014.10.035 PMid:25456126

Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M. et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 2009 року; 106 (33): 14016-14021. https://doi.org/10.1073/pnas.0906549106 PMid:19666525 PMCid:PMC2720852

Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, McConkey DJ. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014; 11 (7): 400-410. https://doi.org/10.1038/nrurol.2014.129 PMid:24960601

Choi W, Porten S, Kim SS, Willis D, Plimack ER, Hoffman-Censits J. et al. Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy. Cancer Cell. 2014; 25: 152-165. https://doi.org/10.1016/j.ccr.2014.01.009 PMid:24525232 PMCid:PMC4011497

Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE. et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA. 2014; 111: 3110-3115. https://doi.org/10.1073/pnas.1318376111 PMid:24520177 PMCid:PMC3939870

Eriksson P, Aine M, Veerla V, Liedberg F, Sjödahl G, Höglund M. Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems. BMC Medical Genomics 2015; 8: 25. https://doi.org/10.1186/s12920-015-0101-5 PMid:26008846 PMCid:PMC4446831

Fishwick C, Higgins J, Percival-Alwyn L, Hustler A, Pearson J, Bastkowski S. et al. Heterarchy of transcription factors driving basal and luminal cell phenotypes in human urothelium. Cell Death Differ. 2017: 24: 809-818. https://doi.org/10.1038/cdd.2017.10 PMid:28282036 PMCid:PMC5423105

Hedegaard J, Lamy P, Nordentoft I. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. 2016 року; 30: 27-42. https://doi.org/10.1016/j.ccell.2016.05.004 PMid:27321955

Ho PL, Kurtova A, Chan KS. Normal and neoplastic urothelial stem cells: Getting to the root of the problem. Nat Rev Urol. 2012; 9 (10): 583-594. https://doi.org/10.1038/nrurol.2012.142 PMid:22890301 PMCid:PMC3468664

Hurst CD, Alder O, Platt FM. Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency. Cancer Cell. 2017; 32: 701-15. https://doi.org/10.1016/j.ccell.2017.08.005 PMid:29136510 PMCid:PMC5774674

Hurst CD, Platt FM, Taylor CF, Knowles MA. Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis. Clin Cancer Res. 2012; 18: 5865-5877. https://doi.org/10.1158/1078-0432.CCR-12-1807 PMid:22932667 PMCid:PMC5081094

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R et al. A consensus molecular classification of muscle-invasive bladder cancer European urology. 2019:pii: S0302-2838 (19) 30695-5. https://doi.org/10.1101/488460

Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015; 15: 25-41. https://doi.org/10.1038/nrc3817 PMid:25533674

Lerner SP, McConkey DJ, Hoadley KA. et al. Bladder cancer molecular taxonomy: summary from a consensus meeting. Bladder Cancer. 2016; 2: 37-47. https://doi.org/10.3233/BLC-150037 PMid:27376123 PMCid:PMC4927916

Lindgren D, Sjödahl G, Lauss M, Staaf J, Chebil G, Lövgren K. et al. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One. 2012; 7 (6): e38863. https://doi.org/10.1371/journal.pone.0038863 PMid:22685613 PMCid:PMC3369837

McConkey DJ, Choi W, Dinney CP. New insights into subtypes of invasive bladder cancer: Considerations of the clinician. Eur Urol. 2014; 66 (4): 609-610. https://doi.org/10.1016/j.eururo.2014.05.006 PMid:24877661

McConkey DJ, Choi W. Molecular Subtypes of Bladder Cancer. Curr Oncol Rep. 2018; 20 (10): 77. https://doi.org/10.1007/s11912-018-0727-5 PMid:30128829

Mo Q, Nikolos F, Chen F, Tramel Z, Lee YC, Hayashi K. et al. Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas. J. Natl. Cancer Inst. 2018; 110 (5): 448-459. https://doi.org/10.1093/jnci/djx243 PMid:29342309 PMCid:PMC6279371

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G. et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017; 171: 540-556.e25.doi: 10.1016 / j.cell.2018.07.036.

Satyal U, Sikder RK, McConkey D, Plimack ER, Abbosh PH. Clinical implications of molecular subtyping in bladder cancer Curr Opin Urol. 2019; 29 (4): 350-356. https://doi.org/10.1097/MOU.0000000000000641 PMid:31158107

Sjödahl G, Eriksson P, Liedberg F, Höglund M. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J Pathol. 2017; 242 (1): 113-125. https://doi.org/10.1002/path.4886 PMid:28195647 PMCid:PMC5413843

Sjödahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S, Veerla S. et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012; 18 (12): 3377-3386. https://doi.org/10.1158/1078-0432.CCR-12-0077-T PMid:22553347

Sjödahl G, Lövgren K, Lauss M, Patschan O, Gudjonsson S, Chebil G. et al. Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol. 2013; 183 (3): 681-691. https://doi.org/10.1016/j.ajpath.2013.05.013 PMid:23827819

Sjödahl G. Molecular Subtype Profiling of Urothelial Carcinoma Using a Subtype-Specific Immunohistochemistry Panel. Methods Mol Biol. 2018; 1655: 53-64. doi: 10.1007 / 978-1-4939-7234-0_5.

Song D, Powles T, Shi L., Lirong Z, Ingersoll MA, Lu YL. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches J Pathol. 2019; 249 (2): 151-165. https://doi.org/10.1002/path.5306 PMid:31102277 PMCid:PMC6790662

Sulaieva ON, Stakhovskiy OE, Shapochka DO Molecular pathology of urothelial carcinoma: prognostic and predictive biomarkers. Practical oncology. 2019; 2 (4): 29-40. https://doi.org/10.22141/2663-3272.2.4.2019.195181

Tan TZ, Rouanne, M., Tan, KT, Huang, RY-J., And Thiery, J.-P. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur. Urol. 2019; 75: 423-432. https://doi.org/10.1016/j.eururo.2018.08.027 PMid:30213523

Thomsen MBH, Nordentoft I, Lamy P, Vang S, Reinert L, Mapendano CK. et al. Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer. Sci. Rep. 2017; 7, 11702.doi: 10.1038 / s41598-017-11291-0.

Volkmer JP, Sahoo D, Chin RK, Ho PL, Tang C, Kurtova AV. et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci USA 2012; 109 (6): 2078-2083. doi: 10.1073 / pnas.1120605109.

Warrick JI, Sjödahl G, Kaag M, Raman JD, Merrill S, Shuman L et al. Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants. Eur. Urol. 2019; 75 (1): 18-22. https://doi.org/10.1016/j.eururo.2018.09.003 PMid:30266310

Weinstein J, Akbani R, Broom B. et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507: 315-322 doi: 10.1038 / nature12965. https://doi.org/10.1038/nature12965 PMid:24476821 PMCid:PMC3962515

Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W. et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 2013; 4: 2612. https://doi.org/10.1038/ncomms3612 PMid:24113773 PMCid:PMC3826632


Abstract views: 92
PDF Downloads: 4
Published
2020-04-14
How to Cite
1.
Sulaieva O, Seleznov O, Shapochka D, Ponomarchuk R, Stakhovsky O, Stefiniv N. MOLECULAR SUBTYPES OF MUSCULAR INVASIVE BLADDER CANCER. Proc Shevchenko Sci Soc Med Sci [Internet]. 2020Apr.14 [cited 2020Jun.5];59(1). Available from: https://mspsss.org.ua/index.php/journal/article/view/254